

All Years ▾ - 111111 - Test Account (Product Shots) ▾

[Advanced Search](#)

Search


Go



24 Apr 2023

This is a test from PR Newswire

This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR...

 [Photos \(1\)](#)  [Documents \(2\)](#)

14 Apr 2023

This is a test from PR Newswire

This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR...

 [Photos \(1\)](#)  [Video \(1\)](#)

10 Apr 2023

This is a test from PR Newswire

This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR...

26 Mar 2023

Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer

Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting¹ NATALEE is the first and only positive Phase III...

15 Mar 2023

This is a test from PR Newswire

This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR...



test

10 Mar 2023

This Is a Test From PR Newswire

This is a test from PR Newswire. This is a test from PR Newswire. "This is a test from PR Newswire." This is a test from PR Newswire. 'This is a test from PR Newswire. This is a test from PR...

 [Photos \(1\)](#)

Show per
page



<https://aall.investorroom.com/news-category?!=6&o=54>